CAMBRIDGE, England, Nov. 10, 2011 /CNW/ - Arecor, the leading company in
advancing aqueous formulation solutions for proteins, peptides and
vaccines, is pleased to announce the appointment of Dr Sarah Howell as
Chief Operating Officer. Dr Howell will be responsible for the
operations of Arecor, with a focus on developing and maintaining
Arecor's upward growth curve ensuring the company continues to deliver
exceptional formulation solutions and performance to the highest
standards across the industry.
Dr Howell has a strong background in clinical and commercial
pharmaceutical product development, manufacture, supply and licensing
across a range of products and therapeutic areas having worked in a
number of leading roles in the pharmaceutical industry, most recently
as Vice President for CMC (Chemistry, Manufacturing & Controls) and
Technical Development for BTG where she had responsibility for CMC
development and supply across BTG's diverse portfolio of products.
Previously she held senior roles in product development and
manufacturing for UCB-Celltech and GlaxoSmithKline. She is also an
active member of the BioIndustry Association (BIA) Manufacturing
Advisory Committee. Dr Howell has an honours degree in Chemistry from
the University of Birmingham and a PhD in Physical Organic Chemistry
from the University of St Andrews.
Tom Saylor, CEO of Arecor stated "Sarah's considerable technical and
leadership experience in the management of development programmes for
biologic drugs, and her capabilities in building partnerships with
major pharmaceutical companies will be a tremendous asset to Arecor as
it expands its business in an industry looking to formulation as an
enabling technology for the new generation of biologic drugs."
Arecor was established to provide formulation solutions to
pharmaceutical and biotech companies developing proteins, vaccines and
diagnostics based upon new insights into stabilization of biologics.
Proteins and vaccines are often fragile entities, and stability can
represent significant constraints in the development of new products
and extending the use of existing products. Arecor has developed
Arestat™, a patented set of tools for stabilization which address the
main pathways of degradation. As a simple reformulation, Arestat™ can
be readily incorporated into standard manufacturing practice, without
covalent modification of the biologic and using excipients approved for
the route of delivery. Arecor currently has active feasibility programs
and licenses with many of the top pharmaceutical and biotech companies
on a wide range of proteins and vaccines.
For further information:
Tom Saylor, CEO
2 Cambridge Science Park